CDC Global Health

FY2017 Funding Recommendation:  
$1.034 billion

 

Funding History

       Enacted   

       President's FY2017 Request   

       InterAction's FY2017 Recommendation


Download PDF

Justification

 Key Facts

  • CDC is the key partner in the PEPFAR program.

  • CDC leads the TB Trials Consortium, which includes a global network of tuberculosis clinical trial sites in over eight countries.

  • CDC is a founding partner of the Measles & Rubella Initiative and provides technical assistance for epidemiological and laboratory surveillance, which is essential to track measles and rubella.

  • In addition to tracking and reporting diseases globally, CDC funds critical product development projects for new health technologies. In 2015, CDC’s NCEZID developed innovative technologies to provide a rapid diagnostic test for the Ebola virus, a new vaccine to improve rabies control, a new and more accurate diagnostic test for the dengue virus, and new tools and drugs to combat antibiotic resistance.

As one of the world’s premier public health agencies with nearly 70 years of experience, the Centers for Disease Control and Prevention (CDC) works with foreign ministries of health, international organizations, and other partners to strengthen health capacity globally, increase security, and support evidence-based global health programs.

The CDC’s global health programs make critical contributions to global issues while also protecting the health of Americans. CDC tracks diseases worldwide, provides public health leadership, helps ministries of health strengthen their research and laboratory infrastructure, trains new health professionals, and conducts research to develop new technologies to combat diseases. This work capitalizes on CDC’s technical expertise and improves the ability of partner countries to lead in the future.

Center for Global Health: $457 million

The CDC Center for Global Health (CDC CGH) works alongside foreign ministries of health to prevent the spread of disease worldwide. For instance, the Division of Parasitic Diseases and Malaria plays a key role in eliminating the global burden of malaria and neglected tropical diseases (NTDs) by improving detection and diagnosis capabilities and advancing research for new interventions. CDC CGH is also a key partner in PEPFAR (the President’s Emergency Plan for AIDS Relief) in over 75 countries, providing technical assistance on scaling up HIV treatment and preventing mother-to-child transmission.

CDC is also a leader in global immunization and disease eradication efforts. Between 1988 and 2010, CDC programs helped reduce new polio cases globally by 99%. The CDC-initiated global campaign to eradicate Guinea worm disease (GWD) has had a major impact, taking GWD from 3.5 million cases per year in 1986 to near eradication today. Through the Measles & Rubella Initiative, of which CDC is a founding partner, measles deaths have decreased by 79%, and 17.1 million deaths were averted from 2000-2014. CDC CGH also provided crucial surveillance and epidemiologic analysis in the African meningitis belt before and after the introduction of the breakthrough MenAfriVac® meningitis A vaccine. It also makes critical contributions to global health capacity building: through its Global Public Health Capacity Development program and the Field Epidemiology Training Program (FELP), CDC CGH has trained over 31,000 epidemiologists in 72 countries on how to detect and rapidly respond to infectious disease outbreaks. This greatly contributed to Nigeria’s ability to contain Ebola during the outbreak there in 2014.

Center for Emerging Zoonotic and Infectious Diseases: $577.485 million

Ongoing research and development at the CDC’s National Center for Emerging Zoonotic and Infectious Diseases (NCEZID) includes new rapid diagnostic tests for plague and rabies. NCEZID continuously investigates and responds to disease outbreaks, such as the Ebola outbreak in West Africa. It also coordinates the implementation of the National Strategy for Combating Antibiotic Resistant Bacteria focused on preventing, detecting, and controlling outbreaks of antibiotic resistant pathogens such as drug resistant tuberculosis.

InterAction’s combined FY2017 funding recommendation for the CDC CGH and NCEZID’s global health efforts is just over $1.034 billion. This will help to bolster programs that continue to advance global health breakthroughs and strengthen and protect the health of individuals worldwide. Specifically, within CDC CGH, this recommendation supports funding for the Global HIV/AIDS, Global Immunization, Parasitic Diseases and Malaria, Global Disease Detection and Emergency Response, and Global Public Health Capacity Development programs. These key programs have important and distinct global health missions – working in over 60 countries – and we recommend that their funding be separate from investments in the Global Health Security Agenda or the emergency Ebola response.

InterAction’s FY2017 recommendation also includes funding for the CDC’s role in the Global Health Security Agenda (GHSA), a whole-of-government initiative that works to build capacity in 30 low- and middle-income countries to detect global health risks rapidly, prevent them when possible, and respond effectively when they occur. The funding is used to train epidemiologists, expand public health emergency management capacity, and build resilient health systems in targeted partner countries. As the world continues to understand the lessons learned from the Ebola crisis, it is important to ensure continued capacity strengthening of global health systems and their ability to respond to new and emerging global health threats. 

It should be noted that this request does not include the domestic funding requested for the Prevention and Public Health Fund within NCEZID.

Success Story

Vaccinated for life: Fighting measles in Benin

Every day, 315 people, mostly children under the age of five, die from measles. But thanks to a vaccination from the Measles & Rubella Initiative, Ileze will not be one of them.

Ileze and his mother, Josephine, live in Benin, a West African nation with geography ranging from large sacred forests to sandy, coastal plains. In November 2014, the family was visited by a Benin Red Cross volunteer, Francoise, who informed them about the vaccination campaign taking place in their city of Cotonou. Josephine agreed to take Ileze to get vaccinated, so Francoise returned the next day to escort them to a nearby vaccination booth. Ileze received a tiny prick – and probably traded in some tears – but he is now vaccinated for life. 

Some 1,000 Benin Red Cross volunteers went door-to-door in three cities to encourage mothers and fathers to vaccinate their children. In all, more than 3 million children in Benin were vaccinated as part of the campaign.

The Measles & Rubella Initiative is one of the world’s most successful partnerships in global health, helping to control the spread of measles and preventing 17.1 million child deaths since 2000.  The Initiative is led by the American Red Cross, United Nations Foundation, U.S. Centers for Disease Control and Prevention (CDC), UNICEF, and the World Health Organization. Each organization has a unique role, with, for example, the Red Cross mobilizing volunteers and the CDC providing technical guidance and laboratory support to ministries of health around the world on disease surveillance, a process used to identify rapidly where the disease is occurring.

The American Red Cross and its partners have helped to vaccinate 2 billion children in more than 80 developing countries.  In many countries, one vaccine is used to protect children against both measles and rubella.  The cost to vaccinate a child against both diseases in low-income countries is less than $2, making the vaccinations one of the most cost effective global health interventions.

Photo: American Red Cross/Javier Acebal

 

Choose to Invest:   2018  |  2017  |  2016  |  2015  |  2014  |  2013  |  2012